Posted by Michael Wonder on 28 Aug 2024
European Commission approves Astellas' Padcev (enfortumab vedotin) in combination with Keytruda (pembrolizumab) for first-line treatment of advanced urothelial cancer
28 August 2024 - European marketing authorisation based on positive overall survival and progression-free survival results from the global Phase 3 EV-302 trial.
Astellas Pharma today announced that the European Commission has granted marketing authorisation for Padcev (enfortumab vedotin, an antibody-drug conjugate) in combination with Keytruda (pembrolizumab, a PD-1 inhibitor) for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy.
